Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Biologic Agents

PreclinicalBiologic

MMedical University of South Carolina

Biologic Agents is one of 44 biologic programs targeting Arthritis. It is currently in Preclinical.

1

Indications

2

Total Trials

1

Active Trials

43

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArthritisActive, not recruiting

ArthritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Arthritis

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Enbrel

Medrol

Azulfidine

Arava

Voltaren

Xeljanz

PPrism Pharmaceuticals

Bayer Aspirin

Actemra

Anjeso

Boehringer Ingelheim

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

ApprovedRecruiting

Chronic Sinusitis

NCT06824649

Clinical

Trials by Indication[1]

Arthritis1 trial

Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs

Completed·SSimon Krabbe··NCT03496831·7,500 enrolled

Chronic Sinusitis1 trial

SMART Use of Biologics in Chronic Rhinosinusitis With Nasal Polyposis

Recruiting·MMedical University of South Carolina·Approved·NCT06824649·504 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Biologic Agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biologic Agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biologic Agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of South Carolina company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: MMedical University of South Carolina

Related News